YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Development of a New Gut-targeted Oral Typhoid Vaccine Ty21a Encasulated within Alginate Enteric Beads

알긴산 장용 비드에 봉입한 새로운 장 표적성 경구용 장티푸스 Ty21a 백신의 개발

  • 장윤정 (중앙대학교 약학대학) ;
  • 정성균 (일양약품(주) 중앙연구소) ;
  • 박동우 (일양약품(주) 중앙연구소) ;
  • 김희준 (일양약품(주) 중앙연구소) ;
  • 김기호 (중앙대학교 약학대학)
  • Published : 2001.10.01
Download PDF
⟨ Previous Next ⟩

Abstract

increase the viability of oral typhoid vaccine during the passage through the castro-intes-tidal tract, numerous attempts have been made including the vaccine coating. However problems such as high death rate during the coating process and its instability in the gastric juice still remain to be solved. In this study, the oral vaccine was made as the micro-enteric beads by adding Salmomella typhi Ty21a cells to sodium alginate solution and spraying onto calcium chloride solution (ionotropic relation method). The vaccine showed more than 90% of its original viability after treating it for 1 hour in the artificial gastric juice (37$^{\circ}C$, 300 rpm). The clearance rate of the Ty21a in the liver and spleen of the mice orally administrated with coated Ty21a was similar to that of the mice intraperitoneally administrated with uncoated Ty21a. The peripheral blood lymphocytes (PBL) isolated from the mice orally administered with this vaccine produced 15.5 fold higher specific IgA antibody titer than that from the control mice administerd with saline solution. furthermore, the mice treated with the coated Ty21a had higher survival rates (50~87%) than the control mice treated with saline solution (0~10%) in the intraperitoneal challenge test with wild type S. typhi Ty21a cells. These results suggest that the alginate-based coating technique is effective to protect live Ty21a from acidic environments, and produces better intestinal immune responses thereby providing a potentially excellent oral typhoid vaccine.

Keywords

References

  1. Prospects for immunizing against Salmonella typhi v.Ⅱ Institute of Medicine.New vaccine development:establishing priorities,Disease of importance in developing countries.
  2. Rev.Infect.Dis. v.8 no.329 Summary of an international workshop on typhoid fever Edelman,R.;Levine,M.M.
  3. Am.J.Trop.Med.Hyg. v.27 no.795 Diagnostic value of the Widal test in areas endemic for typhoid fever Levin,M.M.;Grados,O.;Gilman,R.H.;Woodward,W.E.;Solis-Plaza,R.;Waldman,W.
  4. J.Infect.Dis. v.148 no.599 Typhoid in the United States and the risk to the international traveler Taylor,D.N.;Pollard,R.A.;Blake,P.A.
  5. Bull.World.Health.Organ v.34 no.321 A controlled field trial and laboratory study of five typhoid vaccines in the USSR. Hejfec,L.B.;Salmin,L.V.;Lejtman,M.Z.;Kuz'minova,M.L.;Vasil'eva,A.V.;Levina,L.A.;Bencianova,T.G.;Pavlova,E.A.;Antonova,A.A.
  6. N.Engl.J.Med. v.283 no.739 pathogenesis and immunologic control.2 Hornick,R.B.;Greisman,S.E.;Woodward,T.E.;DuPont,H.L.;Dawkins,A.T.;Snyder,M.J.Typhoid fever
  7. JAMA. v.265 no.756 A new look at typhoid vaccination.Information for the practicing physician Woodruff,B.A.;Pavia,A.T.;Blake,P.A.
  8. A preliminary report.N.Engl.J.Med. v.317 no.1101 Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi Acharya,I.L.;Lowe,C.U.;Thapa,R.;Gurubacharya,V.L.;Shrestha,M.B.;Cadoz,M.;Schulz,D.;Armand,J.;Bryla,D.A.;Trollfors,B.
  9. Lancet v.2 no.8569 Protective activity of Vi capsular polysaccharide vaccine against typhoid fever Klugman,K.P.;Gillbertson,I.T.;Koornhof,H.J.;Robbins,J.B.;Schneerson,R.;Schulz,D.;Cadoz,M.;Armand,J.
  10. J.Gastroenterol.Hepatol v.1 no.67 Gut immunity to typhoid vaccine Ty21a Bartholomeusz,R.C.;Labrooy,J.T.;Johnson,M.;Shearman,D.J.C.;Rowley,D.
  11. Vaccines Polio-historical Robbins,F.C.;Plotkin,S.A.(ed.);Mortimer,E.A.(ed.)
  12. J.Clin.Invest. v.88 no.143 Intestinal immune responses in humans.Oral cholera vaccination induces strong intestinal antibody responese and interferon-gamma production and evokes local immunological memory Quiding,M.;Nordstrom,I.;Kilander,A.;Andersson,G.;Hanson,L.A.;Holmgren,J.;Czerkinsky,C.
  13. J.Infect.Dis. v.153 no.1126 Specific immunoglobulin-secreting human blood cells after peroral vaccination against Salmonella typhi Kantele,A.;Arvilommi,H.;Jokinen,I.
  14. New generation vaccines Vaccines against rotavirus. Offit,P.A.;Clark,H.F.;Kapikian,A.Z.;Levine,M.M.(ed.);Woodrow,G.C.(ed.);Kaper,J.B.(ed.);Cobon,G.S.(ed.)
  15. Infect.Immun. v.4 no.663 Immunity in experimental salmonellosis.Ⅱ.Basis for the avirulence and protective capacity of gal E mutants of Salmonella typhimurium Germanier,R.;Furer,E.
  16. J.Infect.Dis. v.136 no.717 Evaluation of a UDP-galactose-4-epimeraseless mutant of Salmonella typhi as a live oral vaccine Gilman,R.H.;Hornick R.B.;Woodard,W.E.;DuPont,H.L.;Snyder,M.J.;Levine,M.M.;Libonati,J.P.
  17. Lancet. v.336 no.891 Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field tral Levine,M.M.;Ferreccio,C.;Cryz,S.;Ortiz,E.
  18. 약학회지 v.43 no.793 Salmonella typhi Ty21a의 동결건조와 안정성 김세란;박동우;전홍렬;김희준;한성순;김기호;김홍진
  19. Lancet v.1 no.81 Identification of an intestinal immune response using peripheral blood lymphocytes Forrest,B.D.
  20. J.Reticuloendothel.Soc. v.10 no.58 Mechanisms in antimicrobial immunity. Collins,F.M.
  21. Adv.Immunol. v.40 no.153 Immunoglobulin A(IgA):molecular and cellular interactions involved in IgA biosynthesis and immune response Mestecky,J.;McGhee,J.R.
  22. Annu.Rev.Immunol. v.4 no.389 Immunoglobulin A:strategic defense initiative at the mucosal surface Underdown,B.J.;Schiff,J.M.
  23. Vaccine v.10 no.75 The mucosal immune system:from fundamental concepts to vaccine development McGhee,J.R.;Mestecky,J.;Dertzbaugh,M.T.;Eldridge,J.H.;Hirasawa,M.;Kiyono,H.
  24. Infect.Immun. v.64 no.489 Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B.pertussis repiratory infection Jones,D.H.;McBride;B.W.Thornton,C.;O'Hagan,D.T.;Robinson,A.;Farrar,G.H.
  25. Ingect.Immun. v.65 no.853 Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-lactide-co-glycolide) micro-spheres Allaoui-Attarki,K.;Pecquet,S.;Fattal,E.;Trolle,S.;Chachaty,E.;Couvreur,P.;Andremont,A.
  26. J.Infect.Dis. v.167 no.84 Oral immunization with influenza virus in biodegradable microspheres Moldoveanu,Z.;Novak,M.;Huang,W.Q.;Gilley,R.M.;Staas,J.K.;Schafer,D.;Compans,R.W.;Mestecky,J.
  27. Res.Vet.Sci. v.53 no.42 Protective effects of an oral microencapsulated Mycoplasma hyopneumoniae vaccine against experimental infection in pigs Weng,C.N.;Tzan,Y.L.;Liu,S.D.;Lin,S.Y.;Lee,C.J.
  28. J.Control.Release v.39 no.209 Oral vaccination with alginate microsphere systems Bowerstock,T.L.;HogenEsch,H.;Suckow,M.;Porter,R.E.;Jackson,R.;Park,K.
  29. Keystone,CO,J1-002 Transport of antigens and microorganisms by M cells,Proceedings of Mucosal Immunity:New Strategies for Protection Against Viral and Bacterial Pathogens Neutra,M.R.;Giannasca,P.J.;Frey,A.;Zhou,F.;Giannasca,K.T.
  30. Mol.Immunol. v.28 no.287 Biodegradable microspheres as a vaccine delivery system Eldridge,J.H.;Staas,J.K.;Meulbroek,J.A.;McGhee,J.R.;Tice,T.R.;Gilley,R.M.
  31. Curr.Top.Microbiol.Immunol. v.128 no.85 The regulation of lymphocyte traffic Butcher,E.
  32. Vaccine v.10 no.802 Effects of sample processing on the measurement of specific intestinal IgA immune responses Forrest,B.D.